At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

A further presentation during the same symposium at AD/PD 2025 focused on how MRI methods could be accelerated to improve ...

Biogen BIIB announced that the FDA has granted fast track designation to its investigational Alzheimer's disease (AD) drug, ...

The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of ...

Biopharma leaders react to the forced resignation of CBER Head Peter Marks as RFK Jr.’s promised job cuts begin at the FDA; ...

Biogen on Wednesday said BIIB080 is the first tau-targeting antisense oligonucleotide therapy to enter clinical development for Alzheimer's disease and that it is currently being evaluated in a global ...

Eisai & Biogen update on regulatory review of MAA for lecanemab for early Alzheimer’s disease by the European Commission: Tokyo Wednesday, April 2, 2025, 16:00 Hrs [IST] Eisai C ...

In 2025, the CNS market is forecast to surpass $80bn in sales for the first time since 2013, marking a significant turnaround ...

Eisai (TYO: 4523) and Biogen (Nasdaq: BIIB) today provided an update on the ongoing regulatory review of the Marketing ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission (EC) has decided to refer ...

Eli Lilly's Alzheimer's treatment is approved for use in the U.S. but the European Medicines Agency recommended against the ...

A European regulatory committee rejected Eli Lilly's U.S.-approved Alzheimer's disease treatment over potentially dangerous risks of brain bleeding and swelling.